Rituximab and Treg Cells Starts a Phase IIΔ Trial In Youth At Risk Of Diabetes

A new clinical trial is exploring whether two different immune therapies, used alone or in combination, can delay or prevent the onset of T1D in people who are at high risk, but have not yet been diagnosed with T1D. The study will test a cell-based therapy using a patient's own cells (regulatory T cells) and and a drug called rituximab. It involves drawing a person’s blood, isolating a specific…